10th Jun 2016 16:00
SHIRE PLC - Holding(s) in CompanySHIRE PLC - Holding(s) in Company
PR Newswire
London, June 10
Holding(s) in Company
June 10, 2016 - Shire plc (LSE: SHP, NASDAQ: SHPG)
| 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii | Shire plc | |||
| 2 Reason for the notification (please tick the appropriate box or boxes): | ||||
| An acquisition or disposal of voting rights | ||||
| An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached | ||||
| An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments | ||||
| An event changing the breakdown of voting rights | X | |||
| Other (please specify): | ||||
| 3. Full name of person(s) subject to the notification obligation: iii | Deutsche Bank AG | |||
| 4. Full name of shareholder(s) (if different from 3.):iv | Deutsche Bank AG, London Branch | |||
| 5. Date of the transaction and date on which the threshold is crossed or reached: v | 07/06/2016 | |||
| 6. Date on which issuer notified: | 09/06/2016 | |||
| 7. Threshold(s) that is/are crossed or reached: vi, vii | Below notifiable threshold | |||
| 8. Notified details: | |||||||||||||||||
| A: Voting rights attached to shares viii, ix | |||||||||||||||||
| Class/type of shares if possible using the ISIN CODE | Situation previous to the triggering transaction | Resulting situation after the triggering transaction | |||||||||||||||
| Number of Shares | Number of Voting Rights | Number of shares | Number of voting rights | % of voting rights x | |||||||||||||
| Direct | Direct xi | Indirect xii | Direct | Indirect | |||||||||||||
| JE00B2QKY057 | 28,378,378 | 28,378,378 | Below notifiable threshold | Below notifiable threshold | 0 | Below notifiable threshold | 0 | ||||||||||
| B: Qualifying Financial Instruments | |||||||||||||||||
| Resulting situation after the triggering transaction | |||||||||||||||||
| Type of financial instrument | Expiration date xiii | Exercise/ Conversion Period xiv | Number of voting rights that may be acquired if the instrument is exercised/ converted. | % of voting rights | |||||||||||||
| C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi | |||||||||||||||||
| Resulting situation after the triggering transaction | |||||||||||||||||
| Type of financial instrument | Exercise price | Expiration date xvii | Exercise/ Conversion period xviii | Number of voting rights instrument refers to | % of voting rights xix, xx | ||||||||||||
| Nominal | Delta | ||||||||||||||||
| Total (A+B+C) | |||||||||||||||||
| Number of voting rights | Percentage of voting rights | ||||||||||||||||
| Below notifiable threshold | Below notifiable threshold | ||||||||||||||||
| 9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: xxi | ||
| Proxy Voting: | ||
| 10. Name of the proxy holder: | ||
| 11. Number of voting rights proxy holder will cease to hold: | ||
| 12. Date on which proxy holder will cease to hold voting rights: | ||
| 13. Additional information: | ||
| 14. Contact name: | Stacy Otieno | |
| 15. Contact telephone number: | 02075476268 | |
For further information please contact:
| Investor Relations | ||
| Sarah Elton-Farr | [email protected] | +44 1256 894157 |
NOTES TO EDITORS
Shire enables people with life-altering conditions to lead better lives.
Shire is the leading global biotechnology company focused on serving people with rare diseases and other highly specialized conditions. We have best-in-class products available in more than 100 countries across core therapeutic areas including Hematology, Immunology, Neuroscience, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; a growing franchise in Oncology; and an emerging, innovative pipeline in Ophthalmics.
Our employees come to work every day with a shared mission: to develop and deliver breakthrough therapies for the hundreds of millions of people in the world affected by rare diseases and other high-need conditions, and who lack effective therapies to live their lives to the fullest.
www.shire.com
Related Shares:
Shire